

*The Second Nagoya International
Blood and Marrow Transplantation Symposium*

— Current Problems and Its Applications of Hematopoietic Cell Transplantation —

May 24 (Sat), 25 (Sun) 1997

Inuyama JAPAN



*Organized by Nagoya Blood and Marrow Transplantation Group
Kyowa Hakko Kogyo Co., Ltd.*

Greeting

On behalf of the Organizing Committee I cordially welcome all of you to The Second Nagoya International Blood and Marrow Transplantation Symposium.

Bone marrow transplantation (BMT) has now been considered as cure-oriented therapy for hematological malignancies including acute leukemia, chronic myelogenous leukemia and severe aplastic anemia. Particularly, for patients with resistant disease or at high risk to relapse, BMT is the treatment of choice. The clinical application of hematopoietic growth factors such as G-CSF and GM-CSF has been instrumental in improving the prognosis and QOL of the patients following BMT. Peripheral blood stem cell transplantation and umbilical cord blood transplantation have also recently been introduced as new strategies of stem cell transplantation. There remain, however, still serious side effects associated with BMT: GVHD, graft rejection and viral infections. Great efforts are required to the prevention and control of these problems.

This symposium is jointly organized by Nagoya BMT group and Kyowa Hakko Kogyo Co., Ltd to provide an international forum and to exchange the most up-to-date and clinically important information. The theme of this year's symposium is current problems and its applications of hematopoietic cell transplantation. Case conference is also planned to stimulate active discussion on specific clinical problems. We are very happy that many expert investigators selected from across the world will lead the program. We believe that valuable information of clinical relevance will be generated by all speakers and participants through this meeting.

Inuyama with a wooden castle from 16th century and the Kiso river offers a lovely early summer backdrop for our conference. I hope that you enjoy the meeting.



Hidehiko Saito

Hidehiko Saito, M.D.
Chairman, Organizing Committee

Symposium Committees

Chairman

Hidehiko Saito

Nagoya University

Vice Chairman

Makoto Ogawa
Yoshihisa Koderu
Yasuo Morishima

Aichi Cancer Center
The Japanese Red Cross Nagoya First Hospital
Aichi Cancer Center

Secretary General

Hironori Yamada

Nagoya National Hospital

Organizing Committee (Nagoya BMT Group)

Hisashi Fukutani
Noriyuki Hirabayashi
Keizo Horibe
Kouji Kato
Yoshiro Kato
Hiroshi Kojima
Seiji Kojima
Takaharu Matsuyama
Saburo Minami
Kouichi Miyamura
Shin-ichi Mizuno
Yoshihisa Morishita
Toshimasa Nagai
Kouichiro Nagata
Kazuyuki Naito
Tomoki Naoe
Masakazu Nitta
Michinori Ogura
Minoru Saito
Hiroshi Sao
Mitsune Tanimoto
Makoto Utsumi
Kunio Yano
Makoto Yazaki
Shozo Yokomaku

Okazaki Municipal Hospital
Nagoya Daini Red Cross Hospital
Nagoya University
The Japanese Red Cross Nagoya First Hospital
Aichi Medical University
Fujita Health University
The Japanese Red Cross Nagoya First Hospital
The Japanese Red Cross Nagoya First Hospital
The Japanese Red Cross Nagoya First Hospital
Nagoya University
Japanese Red Cross Aichi Blood Center
Kohnan Showa Hospital
Prefectural Aichi Hospital
Anjo Kosei Hospital
Komaki City Hospital
Nagoya University
Nagoya City University
Aichi Cancer Center
Nagoya Ekisaikai Hospital
Meitetsu Hospital
Nagoya University
Nagoya National Hospital
Hamamatsu Medical Center
Nagoya City University
Aichi San-no-maru Hospital

Advisory Committee

Shigetaka Asano

The Institute of Medical Science
The University of Tokyo
Fujita Health University
Okayama University
Fujita Health University
Tokai University
Keio University
Japanese Red Cross Central Blood Center
Japanese Red Cross Aichi Blood Center
Tokai University
Osaka Medical Center for Cancer and
Cardiovascular Diseases

Kouji Ezaki
Mine Harada
Masami Hirano
Tomomitsu Hotta
Yasuo Ikeda
Takeo Juji
Tadashi Kamiya
Shun-ichi Kato
Tohru Masaoka

Tamotsu Matsuda
Hideaki Mizoguchi
Takeshi Nagao
Tatsutoshi Nakahata

Kanazawa University
Tokyo Women's Medical College
Kanagawa Children's Medical Center
The Institute of Medical Science
The University of Tokyo
Kyushu University
Sapporo Medical University
Hamamatsu University
Kyushu University
Japanese Red Cross Hokkaido Blood Center
Mie University
Nagoya National Hospital
Aichi Cancer Center
Jichi Medical School
Aichi Medical University
Tokyo Medical College
Nagoya City University

Yoshiyuki Niho
Youshiro Niitsu
Ryuzo Ohno
Takehiko Sasazuki
Sadayoshi Sekiguchi
Hiroshi Shiku
Masanori Shimoyama
Toshitada Takahashi
Fumimaro Takaku
Shigeru Takamoto
Keisuke Toyama
Ryuzo Ueda

Symposium Office

Central Convention Service, Inc.
1-45 Shirakabe, Higashi-ku, Nagoya 461, Japan
TEL: 052-971-5550 / Fax: 052-951-3600

Scientific Program

— Saturday, May 24 —

- 15:00-15:05 **Opening Remarks**
Hidehiko Saito (Nagoya University)
- 15:05-16:00 **Keynote Address**
Chairperson: Yasuo Morishima (Aichi Cancer Center)
Late Complications of Allogeneic Hematopoietic Cell
Transplantation
Keith M. Sullivan (Fred Hutchinson Cancer Research
Center)
- 16:00-17:30 **Session 1 Table Discussion :**
Prophylaxis and Management for Chronic GVHD and
Post-Transplant Complications
Chairpersons: Hironori Yamada (Nagoya National Hospital)
Seiji Kojima (The Japanese Red Cross Nagoya
First Hospital)
Panelists: Keith M. Sullivan (Fred Hutchinson Cancer Research
Center)
Shimon Slavin (Hadassah University Hospital)
John Barrett (National Institutes of Health)
Akira Hiraoka (Osaka Medical Center for Cancer
and Cardiovascular Diseases)
Hisashi Gondo (Kyushu University)
- 19:00- **Social Meeting**

— Sunday, May 25 —

- 8:30-10:30 **Session 2 : Ex Vivo CTL Induction and Its Therapeutical Applications**
Chairpersons: Shintaro Shiobara (Kanazawa University)
 Hisashi Sakamaki (Tokyo Metropolitan Komagome
 General Hospital)
- A : Adoptive Immune Therapy Using Epstein-Barr Virus(EBV)-Specific
Cytotoxic T Lymphocytes for Severe Chronic Active EBV Infection
 Kiyotaka Kuzushima (Nagoya Ekisaikai Hospital)
- B : Adoptive Immunotherapy for Virus-Associated Complications of Bone
Marrow Transplantation
 Cliona M. Rooney (St. Jude Children's Research
 Hospital)
- C : Immune Reconstitution after Allogeneic Hematopoietic Stem Cell (HSC)
Transplant by the Adoptive Transfer of T Cell Clones
 Stanley R. Riddell (Fred Hutchinson Cancer Research
 Center)
- 10:30-10:45 **Intermission**
- 10:45-12:15 **Session 3 : Adoptive Immunotherapy for Leukemia**
Chairpersons: Satoshi Takahashi (The Institute of Medical Science
 The University of Tokyo)
 Makoto Yazaki (Nagoya City University)
- A : Allogeneic Cell Therapy with Donor Peripheral Blood Cells and
Recombinant IL-2 to Treat Leukemia Relapse after Allogeneic Stem
Cell Transplantation
 Shimon Slavin (Hadassah University Hospital)
- B : Improving Outcome of Allogeneic Bone Marrow Transplantation by
Graft Engineering and Controlled Immunological Reconstitution
 John Barrett (National Institutes of Health)
- 12:15-12:20 **Closing Remarks**
 Yoshihisa Koderu (The Japanese Red Cross Nagoya
 First Hospital)